1
|
Jordao A, Cléret D, Dhayer M, Le Rest M, Cao S, Rech A, Azaroual N, Drucbert AS, Maboudou P, Dekiouk S, Germain N, Payen J, Guerreschi P, Marchetti P. Engineering 3D-Printed Bioresorbable Scaffold to Improve Non-Vascularized Fat Grafting: A Proof-of-Concept Study. Biomedicines 2023; 11:3337. [PMID: 38137558 PMCID: PMC10741522 DOI: 10.3390/biomedicines11123337] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2023] [Revised: 11/29/2023] [Accepted: 12/11/2023] [Indexed: 12/24/2023] Open
Abstract
Autologous fat grafting is the gold standard for treatment in patients with soft-tissue defects. However, the technique has a major limitation of unpredictable fat resorption due to insufficient blood supply in the initial phase after transplantation. To overcome this problem, we investigated the capability of a medical-grade poly L-lactide-co-poly ε-caprolactone (PLCL) scaffold to support adipose tissue and vascular regeneration. Deploying FDM 3D-printing, we produced a bioresorbable porous scaffold with interconnected pore networks to facilitate nutrient and oxygen diffusion. The compressive modulus of printed scaffold mimicked the mechanical properties of native adipose tissue. In vitro assays demonstrated that PLCL scaffolds or their degradation products supported differentiation of preadipocytes into viable mature adipocytes under appropriate induction. Interestingly, the chorioallantoic membrane assay revealed vascular invasion inside the porous scaffold, which represented a guiding structure for ingrowing blood vessels. Then, lipoaspirate-seeded scaffolds were transplanted subcutaneously into the dorsal region of immunocompetent rats (n = 16) for 1 or 2 months. The volume of adipose tissue was maintained inside the scaffold over time. Histomorphometric evaluation discovered small- and normal-sized perilipin+ adipocytes (no hypertrophy) classically organized into lobular structures inside the scaffold. Adipose tissue was surrounded by discrete layers of fibrous connective tissue associated with CD68+ macrophage patches around the scaffold filaments. Adipocyte viability, assessed via TUNEL staining, was sustained by the presence of a high number of CD31-positive vessels inside the scaffold, confirming the CAM results. Overall, our study provides proof that 3D-printed PLCL scaffolds can be used to improve fat graft volume preservation and vascularization, paving the way for new therapeutic options for soft-tissue defects.
Collapse
Affiliation(s)
- Amélia Jordao
- UMR9020–UMR-S 1277–Canther–Cancer Heterogeneity, Plasticity and Resistance to Therapies, CNRS, Inserm, CHU Lille, Oncolille, University Lille, F-59000 Lille, France; (A.J.); (N.G.)
- Lattice Medical, 80 rue du Docteur Yersin, F-59120 Loos, France
| | - Damien Cléret
- Lattice Medical, 80 rue du Docteur Yersin, F-59120 Loos, France
| | - Mélanie Dhayer
- UMR9020–UMR-S 1277–Canther–Cancer Heterogeneity, Plasticity and Resistance to Therapies, CNRS, Inserm, CHU Lille, Oncolille, University Lille, F-59000 Lille, France; (A.J.); (N.G.)
| | - Mégann Le Rest
- Lattice Medical, 80 rue du Docteur Yersin, F-59120 Loos, France
| | - Shengheng Cao
- Lattice Medical, 80 rue du Docteur Yersin, F-59120 Loos, France
| | - Alexandre Rech
- University of Lille, Faculté de Pharmacie, Plateau RMN, UFR3S, F-59000 Lille, France
| | - Nathalie Azaroual
- University of Lille, ULR 7365–GRITA–Groupe de Recherche Sur Les Formes Injectables Et Les Technologies Associées, F-59000 Lille, France;
| | - Anne-Sophie Drucbert
- U 1008 Controlled Drug Delivery Systems and Biomaterials, Inserm, F-59000 Lille, France
| | | | - Salim Dekiouk
- UMR9020–UMR-S 1277–Canther–Cancer Heterogeneity, Plasticity and Resistance to Therapies, CNRS, Inserm, CHU Lille, Oncolille, University Lille, F-59000 Lille, France; (A.J.); (N.G.)
- Centre de Bio-Pathologie, Banque de Tissus, CHU Lille, F-59000 Lille, France
| | - Nicolas Germain
- UMR9020–UMR-S 1277–Canther–Cancer Heterogeneity, Plasticity and Resistance to Therapies, CNRS, Inserm, CHU Lille, Oncolille, University Lille, F-59000 Lille, France; (A.J.); (N.G.)
- Centre de Bio-Pathologie, Banque de Tissus, CHU Lille, F-59000 Lille, France
| | - Julien Payen
- Lattice Medical, 80 rue du Docteur Yersin, F-59120 Loos, France
| | - Pierre Guerreschi
- U 1008 Controlled Drug Delivery Systems and Biomaterials, Inserm, F-59000 Lille, France
- Service de Chirurgie Plastique, CHU Lille, F-59000 Lille, France
| | - Philippe Marchetti
- UMR9020–UMR-S 1277–Canther–Cancer Heterogeneity, Plasticity and Resistance to Therapies, CNRS, Inserm, CHU Lille, Oncolille, University Lille, F-59000 Lille, France; (A.J.); (N.G.)
- Centre de Bio-Pathologie, Banque de Tissus, CHU Lille, F-59000 Lille, France
| |
Collapse
|
2
|
Germain N, Dhayer M, Boileau M, Fovez Q, Kluza J, Marchetti P. Lipid Metabolism and Resistance to Anticancer Treatment. Biology (Basel) 2020; 9:biology9120474. [PMID: 33339398 PMCID: PMC7766644 DOI: 10.3390/biology9120474] [Citation(s) in RCA: 47] [Impact Index Per Article: 11.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/23/2020] [Revised: 12/11/2020] [Accepted: 12/15/2020] [Indexed: 12/13/2022]
Abstract
Simple Summary Cancer cells directly control nutrient uptake and utilization in a different manner from that of normal cells. These metabolic changes drive growth, proliferation of cancer cells as well as their ability to develop resistance to traditional therapies. We review published studies with pre-clinical models, showing the essential roles of lipid metabolism in anticancer drug resistance. We also discuss how changes in cellular lipid metabolism contribute to the acquisition of drug resistance and the new therapeutic opportunities to target lipid metabolism for treating drug resistant cancers. Abstract Metabolic reprogramming is crucial to respond to cancer cell requirements during tumor development. In the last decade, metabolic alterations have been shown to modulate cancer cells’ sensitivity to chemotherapeutic agents including conventional and targeted therapies. Recently, it became apparent that changes in lipid metabolism represent important mediators of resistance to anticancer agents. In this review, we highlight changes in lipid metabolism associated with therapy resistance, their significance and how dysregulated lipid metabolism could be exploited to overcome anticancer drug resistance.
Collapse
Affiliation(s)
- Nicolas Germain
- UMR 9020–UMR-S 1277–Canther–Cancer Heterogeneity, Plasticity and Resistance to Therapies, Institut de Recherche contre le Cancer de Lille, University Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France; (M.D.); (M.B.); (Q.F.); (J.K.)
- Banque de Tissus, Centre de biologie-pathologie, CHU Lille, F-59000 Lille, France
- Correspondence: (N.G.); (P.M.); Tel.: +33-3-20-16-92-20 (P.M.)
| | - Mélanie Dhayer
- UMR 9020–UMR-S 1277–Canther–Cancer Heterogeneity, Plasticity and Resistance to Therapies, Institut de Recherche contre le Cancer de Lille, University Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France; (M.D.); (M.B.); (Q.F.); (J.K.)
| | - Marie Boileau
- UMR 9020–UMR-S 1277–Canther–Cancer Heterogeneity, Plasticity and Resistance to Therapies, Institut de Recherche contre le Cancer de Lille, University Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France; (M.D.); (M.B.); (Q.F.); (J.K.)
- Service de Dermatologie, Hopital Claude Huriez, CHU Lille, F-59000 Lille, France
| | - Quentin Fovez
- UMR 9020–UMR-S 1277–Canther–Cancer Heterogeneity, Plasticity and Resistance to Therapies, Institut de Recherche contre le Cancer de Lille, University Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France; (M.D.); (M.B.); (Q.F.); (J.K.)
| | - Jerome Kluza
- UMR 9020–UMR-S 1277–Canther–Cancer Heterogeneity, Plasticity and Resistance to Therapies, Institut de Recherche contre le Cancer de Lille, University Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France; (M.D.); (M.B.); (Q.F.); (J.K.)
| | - Philippe Marchetti
- UMR 9020–UMR-S 1277–Canther–Cancer Heterogeneity, Plasticity and Resistance to Therapies, Institut de Recherche contre le Cancer de Lille, University Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France; (M.D.); (M.B.); (Q.F.); (J.K.)
- Banque de Tissus, Centre de biologie-pathologie, CHU Lille, F-59000 Lille, France
- Correspondence: (N.G.); (P.M.); Tel.: +33-3-20-16-92-20 (P.M.)
| |
Collapse
|